Kornimate/medical-research-clean huggingface dataset:
wearable sensors and artificial intelligence for carbohydrate counting

Conditions: Type 2 Diabetes

Summary: this is a one-group pilot study where chinese immigrants who are english speaking with t2d from nyu langone health and nyu brooklyn family health center (sunset park) will be recruited.

to evaluate the estimation accuracy using ebutton, researchers will collect carbohydrate data via weighing food by registered dietitian nutritionist (rdn) ("gold standard") (2 days/week at research labs) and food diaries by participants (2 days/week at research labs and 3 days/ week at participant home). then, the estimated carb grams will be compared head to head among each other. assessment will be at 0 and 2 weeks, including surveys and qualitative audio interview.

Eligibility criteria:
inclusion criteria: * ≥18 years old * diagnosed with t2d at least one year prior * self-identified as first- or second-generation chinese immigrants * feel comfortable communicating in english, the reason is that the questionnaires/surveys are validated in english * have a computer and internet connection exclusion criteria: * plan frequent travel or vacations or plan to relocate in the next five weeks * have serious diabetes-related complications, physical illness, or mental illness (e.g., schizophrenia, bipolar disorder, or substance abuse) that would preclude participation * have severe cognitive impairments (e.g., dementia, intellectual disability)
resumption of enteral feeding after bowel anastomosis

Conditions: Enhanced Recovery After Surgery; Hospital Stay, Length of Stay in Hospital From Time of Surgery Till Discharge; Defecation; Vomiting, Postoperative; Anastomotic Leak; Flatus

Summary: resumption of oral feeding after small intestine surgery is a matter of controversy .some surgeons advocate early resumption while others don't.early feeding is initiated as soon as the patient recovers from effects of anaesthesia, while late resumption is started after 24-48 hours after surgery.recent studies and guidelines suggest early feeding. the aim of this study is to compare the early and late resumption of oral feeding.


Eligibility criteria:
inclusion criteria: * all patients undergoing small bowel anastomosis for any indication in elective setting * patients of age between 15 to 65 years. * all genders exclusion criteria: * patient using glucocorticoids or other immunosuppressive drugs * non conseting individuals * patient having history of gastrectomy

Keywords: enhanced recover after surgery hospital stay postoperative vomiting anastomotic leak
weightbearing assessment of tarsal instability

Conditions: Adult-acquired Flatfoot Disorder (AAFD)

Summary: the purpose of this study is to compare the average joint motion and joint axis orientation of the hindfoot bones between patients diagnosed with adult-acquired flatfoot disorder (aafd) and a control group of patients without foot deformity, using weight-bearing ct technology.


Eligibility criteria:
symptomatic group: inclusion criteria: 1. adult patients (ages 18 -80 years old) diagnosed with stage 2 aafd exclusion criteria: 1. previous surgery 2. infection 3. tumor in the affected foot 4. pregnancy control group: inclusion criteria: 1. adult patients (ages 18 -80 years old) without foot deformity exclusion criteria: 1. history of previous foot and ankle surgery 2. foot deformity 3. known foot and ankle pathology 4. pregnancy

Keywords: adult-acquired flatfoot disorder (aafd) flexible flatfoot computed tomography (ct)
ai-based multimodal multi-tasks analysis reveals tumor molecular heterogeneity, predicts preoperative lymph node metastasis and prognosis in papillary thyroid carcinoma

Conditions: Papillary Thyroid Carcinoma; Molecular Heterogeneity; Multi-model Analysis; Artificial Intelligence; Lymph Node Metastases; Disease-free Survival

Summary: this study involved a comprehensive analysis of 256 ptc patients from sun yat-sen memorial hospital of sun yat-sen university (sysmh) and 499 patients from the cancer genome atlas. dna-based next-generation sequencing (ngs) and single-cell rna sequencing (scrna-seq) were employed to capture genetic alterations and tme heterogeneity. a deep learning multimodal model was developed by incorporating matched histopathology slide images, genomic, transcriptomic, immune cells data to predict lnm and disease-free survival (dfs).


Eligibility criteria:
inclusion criteria: ≥ 18 years of age diagnosis of papillary thyroid carcinoma at least one months before trial willing to return for required follow-up (posttest) visits exclusion criteria: the patient requires valve or other likely surgery the patient is unable to carry out any physical activity without discomfort the patient had thyroid ache within three months prior to enrollment the patient refuses to give informed consent the patient is a candidate for coronary bypass surgery or something similar
l-csa in the prevention of bronchiolitis obliterans syndrome (bos) in lung transplant (lt) patients

Conditions: Bronchiolitis Obliterans

Summary: immunosuppression is a key intervention in patients with solid organ transplant and is usually achieved by combination therapy with systemic csa or tacrolimus with azathioprine, mycophenolate mofetil (mmf), or corticoids. however, the outcomes after lung transplantation are poor when compared with those after heart, kidney, or liver transplantation, with a survival rate of only 55% for recipients of lung transplants. additional application of aerosolised l-csa should suppress t-cell activation in the lung tissue and subsequently bos development. the overall purpose of this phase-ii/iii study is to obtain efficacy and safety data of l-csa in the prevention of bos.

preventive therapeutic intervention by l-csa is primarily aimed to suppress t-lymphocyte suppression and inflammatory responses and secondly to prevent fibrotic effects making it more likely to be effective in early stages of bos. early development of bos, which mostly will not be diagnosed, and acute organ rejections are strongly patho-physiological associated. prevention of the very early development of chronic rejection by l-csa post ltx may be the ideal starting point for imp application.

Eligibility criteria:
inclusion criteria: 1. patient's written informed consent 2. received a single lung, bilateral lung or heart/lung transplantation between 6 weeks and 26 weeks prior to first imp administration. 3. male or female, 18 years of age 4. capable of self-administration of medications 5. capable of understanding the purpose and risk of the clinical trial 6. received the following immunosuppressive agents and dosages for maintenance therapy: 1. tacrolimus and 2. mycophenolate mofetil (mmf) 1 to 3 g/day and 3. prednisone or any other steroid therapy; tapered down 7. female patients with childbearing potential must have a negative urine pregnancy test prior to first imp administration. 8. estimated life expectancy \> 6 month exclusion criteria: 1. any previous episode of bronchiolitis obliterans (bo) or bronchiolitis obliterans syndrome (bos) of grade 1 or higher 2. any active invasive bacterial, viral or fungal infection 3. received systemic maintenance immunosuppressive therapy other than listed in the inclusion criteria 4. received any systemic or topical ciclosporin a within 5. received any systemic or topical rosuvastatin 6. current mechanical ventilation 7. received a lung re-transplantation 8. pregnant or breast feeding woman 9. has known hypersensitivity to ciclosporin a 10. has a serum creatinine value of more than 265 µmol/l (3 mg/dl) 11. unlikely to comply with visits, inhalation procedures or spirometric measurements 12. receipt of an investigational drug within 4 weeks prior to first administration of imp 13. any co-existing medical condition that in the investigator's judgement 14. psychiatric disorders or altered mental status 15. patient was previously enrolled in the present clinical trial
efficacy and safety of omega-3 fatty acids(omacor®) for the treatment of immunoglobulin a nephropathy

Conditions: IgA Nephropathy

Summary: the purpose of this study is to compare omega-3 fatty acids with placebo for efficacy in retardation of increase of serum creatinine(scr) in iga nephropathy

in the current clinical study, attempts are made to assess the safety and efficacy of omega-3 fatty acids by comparing between omega-3 fatty acids and the placebo in korean patients with iga nephropathy.

Eligibility criteria:
inclusion criteria: * patient of both sexes age 18 or above * biopsy-proven iga nephropathy * baseline serum creatinine ≥ 1.2mg/dl(female),≥ 1.4mg/dl(male) * able to give written informed consent exclusion criteria: * hypertension sbp\>160mmhg and/or dbp\>100mmhg * subject, who in the investigator's opinion, has a systemic disease that would contraindicate participation in this study * use of omega-3 fatty acids or analog supplement * pregnancy or breast feeding at time of entry or unwillingness to comply with measures for contraception * current or recent (within 30 days) exposure to any investigational drug * subject who has hypersensitivity to this agent as a previous illness * low platelet(\<100,000/㎕) or the subject who has a high risk of bleeding * use of corticosteroid during the treatment period or less than 3 months prior to the screening * use of anticoagulant during the treatment period or within 1 month or 6 half lives prior to screening * subject who in the investigator's opinion, would be confronted with a difficulty
nexium dyspepsia/ast

Conditions: Gastrointestinal Disease; Signs and Symptoms, Digestive; Dyspepsia

Summary: the aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.


Eligibility criteria:
inclusion criteria: * at least 3 months of symptoms of pain or burning centered in the upper abdomen prior to enrollment. * helicobacter pylori test performed at enrollment must be negative (helicobacter pylori is a bacterial infection of the stomach). exclusion criteria: * patients with symptoms of other gastrointestinal diseases, such as gastroesophageal reflux disease (gerd), irritable bowel syndrome (ibs) or inflammatory bowel disease (ibd). * helicobacter pylori eradication treatment during the last 12 months prior to enrollment.
effect of niacin/laropiprant on postprandial lipoprotein metabolism in patients with dyslipoproteinemia

Conditions: Hyperlipoproteinemia; Metabolic Syndrome

Summary: the study is designed to evaluate the effect of niacin/laropiprant on postprandial lipoprotein metabolism, postprandial glucose metabolism, postprandial monocyte function, and postprandial biomarkers of endothelial dysfunction and inflammation.


Eligibility criteria:
inclusion criteria: * male subjects or postmenopausal female subjects aged between 19-70 years * high risk patients (procam risk ≥20%) on a stable statin-therapy, but at least simvastatin 20 mg/d * hdl-cholesterol ≤50 mg/dl and /or triglycerides 150-400 mg/dl and/or ldl-cholesterol 70 - 150 mg/dl * lipoprotein (a) \< 30 mg/dl * patients may have normal glucose metabolism (normal homa), be insulin resistant (abnormal homa), have impaired fasting glucose or impaired glucose tolerance but not diabetes mellitus. * without niacin therapy for at least 6 months * dosage of any concomitant medication has been stable for at least 3 weeks * if female, postmenopausal (absence of menstruation for at least 12 months or absence of menstruation \> 6 months with fsh \> 40 ng/ml respectively oestrogen \< 20 pg/ml) exclusion criteria: * subjects with additional causes for hyperlipoproteinemia * diabetes mellitus or antidiabetic medication * subject has history of cardiovascular ischemia in previous 3 months or acute myocardial infarction or unstable angina * history of psychiatric disorder or cognitive impairment that would interfere with participation in the study * history of alcoholism * contraindication against niacin and/or laropiprant * subject has participated in an investigational study within 30 days prior to study initiation * fasting triglycerides \>400 mg/dl * life-threatening disease (e.g. cancer) * renal insufficiency (gfr ≤ 30 ml/min ) * major hepatic impairment * known allergic reaction/intolerance against niacin and/or laropiprant * active peptic ulcer disease
axitinib (ag 013736) as second line therapy for metastatic renal cell cancer

Conditions: Kidney Neoplasms

Summary: the study is designed to demonstrate that axitinib (ag-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis * evidence of measurable disease * must have failed one prior systemic first-line regimen for metastatic renal cell cancer exclusion criteria: * prior treatment for metastatic renal cell cancer with more that one systemic first line therapy * major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug

Keywords: axitinib in second line treatment of patients with metastatic renal cell cancer
estimating prevalence of inherited disorders of sulfur amino acids metabolism in patients with psychotic disorders.

Conditions: Inherited Metabolic Disorder of Nervous System; Schizophrenia

Summary: screening for sulfur amino acid metabolism pathologies using a sulfitest in adult patients with psychotic disorder.

psychotic disorder is a public health problem, with a cumulative incidence in the general population estimated at 3%. although in most cases the origin is purely psychiatric, psychotic disorder can also represent a mode of entry into many organic pathologies. among these, hereditary metabolic diseases, although rare in the general population, hold a special place, especially in view of their potentially treatable character. however, the identification of this type of disease within the mass of patients with psychotic disorders can be an extremely complex task, and has been the subject of scientific interest for many years. recently, at the grenoble alpes university hospital, a new hereditary metabolic disease that causes psychotic disorders has been discovered. this disease was identified in a family of patients, most of whom had psychotic disorders, and all of whom had deep cystic leukoencephalopathy on mri and a positive sulfitest. the discovery of this new hereditary metabolic disease raises the question of its prevalence in patients with psychotic disorders, and more generally of the prevalence of diseases of sulfur amino acid metabolism. psynit study therefore aims, using the sulfitest, to detect hereditary diseases of sulfur amino acid metabolism in a sample of patients with psychotic disorders without known organic etiology. the discovery of other patients would raise the question of screening more widely for this type of pathology, and would modify the management of the patients thus screened in terms of follow-up and possibly treatment.

Eligibility criteria:
inclusion criteria: * male or female 18 years of age and older, * followed for a psychotic disorder, * with no known organic etiology for the psychotic disorder, * not having formulated its opposition to participation in the study (or his/her tutor/curator), * affiliated with the social security system. exclusion criteria: * patients protected by law (minors, pregnant or breastfeeding women, deprived of liberty or hospitalized under constraint, under administrative or judicial supervision) except patients under tutorship or curatorship.

Keywords: nit1 sulfitest inherited metabolic disorder psychotic disorders
the therapeutic workplace intervention in community settings

Conditions: Drug Abuse; Alcohol Abuse

Summary: methadone is effective for heroin addiction, but many methadone patients continue to use cocaine. high magnitude and long-duration voucher-based abstinence reinforcement, in which participants receive vouchers exchangeable for goods and services contingent on providing drug-free biological samples, is one of the most effective treatments for drug addiction and can maintain cocaine abstinence over extended periods of time. our research on a model therapeutic workplace has shown that employment-based abstinence reinforcement, in which participants must provide drug-free urine samples to access the workplace and maintain maximum pay, can maintain cocaine abstinence and reduce drug-related hiv risk behaviors over extended time periods. our next challenge is to disseminate employment-based reinforcement for the treatment of drug addiction. the investigators propose to develop, manualize, and pilot test a community-friendly therapeutic workplace intervention that can be implemented widely throughout the us and elsewhere. methadone patients who use injection or crack cocaine during methadone treatment will be invited to participate (n = 58) and randomly assigned to one of two groups: usual care (control) group or community therapeutic workplace group. as in our prior implementations of the therapeutic workplace intervention, community therapeutic workplace participants will enroll in phase 1 to initiate drug abstinence and acquire job skills. participants who initiate abstinence and acquire job skills in phase 1 will be hired into community workplaces with collaborating employers in phase 2. during phase 2, employment-based abstinence reinforcement contingencies will be implemented using procedures for workplace drug and alcohol testing overseen by the us department of transportation. using this system, a national provider of drug-free workplace services will arrange random drug testing and employment-based abstinence reinforcement contingencies in which employees will be required to remain drug-free to maintain employment. the investigators hypothesize that participants in the community therapeutic workplace group will provide more drug-free samples, and engage in fewer hiv-risk behaviors than participants in the usual care group. the study will provide vital information on the acceptability of the intervention to participants and employers, and provide preliminary data on the effectiveness of the investigators procedures to maintain abstinence and promote employment.


Eligibility criteria:
inclusion criteria: * ≥18 years old * enrolled in methadone treatment in baltimore * unemployed * provide a cocaine-positive urine sample at intake * meet dsm iv criteria for cocaine dependence * report using injection or crack cocaine exclusion criteria: * report current suicidal or homicidal ideation * have a severe psychiatric disorder
proton radiation therapy (rt) for the treatment of pediatric rhabdomyosarcoma

Conditions: Rhabdomyosarcoma

Summary: the main purpose of this study is to see if using proton beam radiation therapy instead of photon beam radiation therapy can reduce side effects from radiation treatment for rhabdomyosarcoma. photon beam radiation is the standard type of radiation for treating most rhabdomyosarcoma and many other types of cancer. photon beam radiation enters the body and passes through healthy tissue, encounters the tumor, then leaves the body through healthy tissue. a beam of proton radiation enters the body and passes through healthy tissue, encounters tumor, but then stops. this means that less healthy tissue is affected by proton beam radiation than by photon beam radiation.

* a special device is made for each participant to help them hold still during the treatment. this may be in the form of a mask or a custom made foam cradle depending on the area to be treated. * radiation treatments will be given once per day, 5 days a week for a total of 4 to 6 weeks, depending upon how much total dose the tumor requires. * participants will be seen once per week by their radiation doctor to monitor health and record any side effects from treatment. * after the radiation treatments are completed, participants will be required to undergo further tests and evaluations for several years following treatment.

Eligibility criteria:
inclusion criteria: * patients with biopsy proven newly diagnosed rhabdomyosarcoma. * patients less than or equal to 30 years of age. * patients must be treated with a standardly accepted chemotherapy regimen. * may not have metastatic disease unless aged 2-10 with embryonal histology. * must be willing to receive follow-up care for a minimum of five years after treatment at mgh and annual visits unless it is too difficult to return to mgh for follow-up care. in that event, they must be willing to have their outside medical information released to us to track the results. * timing of radiation must be according to the irb protocol upon which the patient is treated within either 35 days of last chemotherapy or surgery. exclusion criteria: * life expectancy of less than 2 years. * co-morbidities that would make the use of radiation too toxic to deliver safely, such as serious local injury or collagen vascular disease. * patients who are pregnant * previous treatment with radiation therapy.

Keywords: pediatric rhabdomyosarcoma proton radiation therapy
a study of a technology-enabled disease management program to reduce hospitalizations for heart failure

Conditions: Congestive Heart Failure; Diastolic Heart Failure; Systolic Heart Failure

Summary: this study will randomize participants with a diagnosis of congestive heart failure and at least one risk factor for hospitalization to either a tablet computer and web based disease management program or a telephone based disease management program. both interventions are home based with heart failure education and symptom monitoring provided by nurse managers. the nurse managers are in close communication with both the participants and the participants' physicians . the components of the disease management program have been developed at tufts medical center and the new england quality care alliance with studies showing improved clinical outcomes, including reduced hospitalizations. the goal of this study is to transition this successful home monitoring and disease management program to a tablet computer and web-based implementation to both improve clinical outcomes (reducing hospitalizations and improving self-perceived health status) and improve provider-patient satisfaction. we hypothesize that the tablet computer based disease management will decrease heart failure hospitalizations.


Eligibility criteria:
inclusion criteria: 1. patients age ≥ 18 with a primary care provider or specialist that is participating within the collaborative health aco. 2. patient able to consent 3. a diagnosis of heart failure with at least one of the following risk factors: * hospitalization for heart failure within the prior year * nyha class iii-iv symptoms * most recent bnp ≥ 300 pg/ml (or nt-probnp ≥ 600 pg/ml) as long as within 90 days prior to enrollment exclusion criteria: 1. acute myocardial infarction, pci or cabg within 30 days before enrollment 2. planned revascularization procedures, cardiac mechanical support implantation, cardiac transplantation, or other cardiac surgery within 30 days following study randomization. 3. illness other than heart failure deemed the principal limitation to life expectancy or principal cause of disability 4. severe angina as the principal cause of limitation 5. uncorrected valvular disease, except where valvular regurgitation was considered to be secondary to severe left ventricular dilation, or where surgical correction is deemed excessively risky or declined by the patient. 6. moderate to severe dementia such that unable to participate in disease management program 7. severe visual or auditory disability such that unable to participate in disease management program 8. hospice care 9. listed for heart transplantation 10. no access to a working telephone 11. homeless or no stable home environment 12. not speaking a language in which the educational documents have been translated

Keywords: congestive heart failure disease management hospitalization